Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Features

657 Features
Efficacy and improved tolerability of Hypericum perforatum extract, WS 5570, compared to paroxetine in patients with moderate to severe depression

16 Mar 05

Depression is the most common mental disorder worldwide affecting around 120 million people globally. The depression market is the largest segment of the CNS market with global sales of US$15.5 billion in 2003 although this figure is dropping as generic equivalents of past blockbusters are launched. Although the depression market has matured, key areas of unmet clinical need will have to be addressed in order to drive further growth of the market. These include improvements in the safety/tolerab
LeadDiscovery

Valeant Pharmaceuticals' remofovir mesylate, an improved adefovir prodrug for targeted and tolerable treatment of hepatitis B (HBV) infection

16 Mar 05

According to the WHO, 350-400 million individuals are chronically infected with the hepatitis B virus (HBV). Chronic infection with hepatitis viruses causes cirrhosis and hepatocellular carcinoma, both devastating diseases with few treatments and the demand for effective treatments for hepatitis infection is therefore high. Lamivudine dominates first-line therapy for HBV (see our feature on hepatitis B & C). Gilead's Adefovir prodrug (Hepsera) represent a second line option although nephrotoxici
LeadDiscovery

Long term beta adrenergic receptor blockade following myocardial infarction promotes myocardial angiogenesis

16 Mar 05

Beta blockers reduce heart rate and myocardial contractility thereby reducing myocardial work load. Diastolic perfusion time is also lengthened by beta blockers supporting the use of this drug class as acute and chronic treatment following myocardial infarction. Studies have demonstrated that beta blockers can reduce total mortality, nonfatal myocardial infarction and sudden death in patients who have already suffered a myocardial infarction by 20-30%. Despite the potential benefit of beta block
LeadDiscovery

Eisai's retinoic acid (RAR)-alpha receptor agonist as a candidate therapy for the treatment of lupus nephritis

16 Mar 05

Lupus is a chronic inflammatory disease that can affect various parts of the body, especially the skin, joints, blood, and kidneys. For most people, lupus is a mild disease affecting only a few organs. For others, it may cause serious and even life-threatening problems. In particular lupus nephritis claim a significant number of lives. More than 16,000 Americans develop lupus each year. It is estimated that 500,000 to 1.5 million Americans have been diagnosed with lupus. Current treatments focus
LeadDiscovery

The Best of Both Worlds

08 Mar 05

Imagine the benefits of working for a global organisation which turns over over £4 billion per year worldwide but is primarily family owned and complete with family values? This is exactly what Merck offers.
Pharmaceutical Field

Bipolar Disorder

03 Mar 05

Bipolar affective disorder – previously referred to as manic depression – is a psychiatric disorder affecting at least 1% of the UK population, and depending on the definition used, may affect as many as 5% of the population. A recent World Health Organization analysis of the major global causes of disability, economic and social burden, indicated that bipolar affective disorders are ranked in the top ten, and account for 2.5% of total years lost to disability across all age groups.
CSF Medical Communications

Emerging oncology treatments: A focus on targeted therapeutics, supergeneric reformulations and supportive care

02 Mar 05

The oncology market is the third largest pharmaceutical market, behind the cardiovascular and CNS therapy areas, and is currently experiencing strong growth. Worth an estimated $35 billion in 2003, analysts predict that the sector will grow to $60 billion by 2010, yielding a compound annual growth rate of 8% over this period. Major changes are however occurring in the oncology market. Cytotoxics, a cornerstone of oncology, are reaching patent expiry and the last cytotoxic genericization is expec
LeadDiscovery

Emerging treatments for inflammatory bowel disease (IBD)

20 Feb 05

Ulcerative colitis and Crohn’s disease, known collectively as inflammatory bowel disease (IBD) currently affects 0.5-1% of the Western world’s population. This translates to over one million people in America (525,000 Ulcerative Colitis, 490,000 Crohn's Disease) and four million people worldwide. Sufferers experience a range of gastrointestinal symptoms, including diarrhea, rectal bleeding and abdominal pain resulting in weight loss as well as other extraintestinal manifestation such as skin and
LeadDiscovery

Alzheimer’s Disease

15 Feb 05

Dementia currently affects over 750,000 people in the UK, with 650,000 new cases arising each year across the European Union. Alzheimer’s disease is the major cause of dementia and accounts for about 55% of all cases. It is a progressive, degenerative disease which affects memory, judgement, orientation, behaviour and language skills, and can place an enormous stress on family caregivers, 49% of whom are over 70 years of age.
CSF Medical Communications

InterMune's hepatitis strategy gets the right response

11 Feb 05

A significant rise in sales of InterMune's hepatitis drug Infergen, from $9.3 million in 2003 to $22.3 million in 2004, is the result of the company's focus on marketing Infergen to HCV non-responders. In targeting this vital patient sub-group, InterMune could gain a useful head start in an area of hepatitis treatment that is set to become fiercely competitive in the years ahead.
Datamonitor

Asthma: alternative anti-inflammatory agents needed for patient subgroup

04 Feb 05

Five million adult asthmatics may have predominantly neutrophilic inflammation. Whilst this phenotype is usually associated with severe asthma, it may be more prevalent across the range of disease severities than originally thought. The emergence of this phenotype in asthma raises important implications for treatment practice.
Datamonitor

Eisai's retinoic acid (RAR)-alpha receptor agonist as a candidate therapy for the treatment of lupus nephritis

03 Feb 05

Lupus is a chronic inflammatory disease that can affect various parts of the body, especially the skin, joints, blood, and kidneys. For most people, lupus is a mild disease affecting only a few organs. For others, it may cause serious and even life-threatening problems. In particular lupus nephritis claim a significant number of lives. More than 16,000 Americans develop lupus each year. It is estimated that 500,000 to 1.5 million Americans have been diagnosed with lupus. Current treatments focus
LeadDiscovery

Progress in the treatment of peripheral arterial disease (PAD)

27 Jan 05

In contrast to coronary and cerebral artery disease, peripheral arterial disease (PAD) remains an under-appreciated condition that despite being serious and extremely prevalent is rarely diagnosed and even less frequently treated. This situation is now changing as physician awareness grows in parallel with increased use of existing therapeutics and the development of improved cardiovascular agents, gene therapies and devices
LeadDiscovery

Free Sales Force Effectiveness industry trends report.

27 Jan 05

Get your hands on this unique free intelligence from eyeforpharma's recent Sales Force Effectiveness conferences in Europe and the USA.
Selma Nawaz

Migraine

24 Jan 05

For people with migraine, today’s world is a better world than the one their parents knew. The last 15 years have seen major advances, giving us not only a much clearer understanding of the disorder but also considerably more effective therapies. Treatments exist that – if made available and used in the right way – can substantially relieve the majority of people affected by migraine.
CSF Medical

Epilepsy

17 Jan 05

Epilepsy is a common condition in the UK, with an incidence of approximately 80 cases per 100,000 population per year, and a prevalence of 5–10 cases per 1000. Yet, despite this high prevalence, it remains a stigmatising condition, with occupational and social disadvantages imposed on the individual. Epilepsy is difficult to diagnose, requiring a detailed history, and is complex to manage.
Csf Medical Communications

Addressing the unmet need of diabetics with new generation non-insulin antidiabetics

17 Jan 05

It is estimated that there are more than 38 million people in the seven major markets with diabetes and this figure is set to rise to 50 million in 2012. However, despite this vast potential patient population, low diagnosis rates, the chronic nature of the disease, the need for combination therapy, the lack of an oral antidiabetic agent offering effective long-term therapy and the association of injectable therapies with poor patient compliance mean that a broad spectrum of unmet needs exists.
LeadDiscovery

Morgan Levy (formally E-Focus Resourcing) has rebranded.

13 Jan 05

Morgan Levy (formally E-Focus Resourcing) has pleasure in announcing that we have re-branded to Morgan Levy with effect from January 2005.
GARY M BRITNELL

SOCS1 silencing dramatically increases the anti-cancer efficacy of dendritic cell vaccines

04 Jan 05

The development of dendritic cell vaccines to fight cancer is an attractive therapeutic approach. Usually this strategy involves pre-pulsing dendritic cells with cancer antigen and maturing them ex vivo prior to administering them to patients. Limitations to this approach include the cumbersome nature of antigen loading and maturation and the limited immunogenicity of the cells. The company BioVEX have successfully developed viruses to load dendritic cells with antigen. Researchers from Baylor h
LeadDiscovery

Sorafenib offers hope in the battle for liver cancer survival

20 Dec 04

The outlook for hepatocellular carcinoma (HCC) sufferers is bleak - current medication has a five-year survival rate for those with liver cancer of less than 5% in the developed world and even lower in developing countries. However, patients in trials of a new drug called Sorafenib have seen their survival times double. Datamonitor's Dr Lorna Fern investigates...
Datamonitor

“Get behind Clean Hospital Summit” call as patient pressure rises

14 Dec 04

Britain’s hospital patients, led by Claire Rayner, today called for healthcare professionals to get behind the UK’s first ever Clean Hospitals Summit, planned for April 14-15, 2005.
Anna Harris/ Alan Murray

Developments in oncolytic viruses - An emerging approach to cancer therapeutics

13 Dec 04

This report introduces the emerging field of oncolytic viruses and the various benefits that oncolytic virology can offer in the treatment of cancer. Clinical data suggest that oncolytic viruses may offer therapeutic advantages over existing cancer therapies such as chemotherapy and radiation and may even act synergistically with these conventional approaches. This report evaluates preclinical and clinical data on oncolytic viruses that have entered the clinic.
LeadDiscovery

Serevent warning focuses attention on the need for combination therapy

10 Dec 04

The recent announcement by the FDA's associate director for science and medicine that sales of GlaxoSmithKline's asthma drug Serevent should be restricted, or halted, led to an estimated 3.8% fall in the company's share price. However, Datamonitor's Laura Harris comments that, with Seretide accounting for the majority of GSK's asthma sales, the panic may be premature.
Datamonitor

Arava: the 'sixth drug' that may soon be under fire

08 Dec 04

At a recent hearing into the Vioxx affair, the FDA's Dr David Graham named five drugs that he considers too dangerous to be on the market. However, in his testimony, Dr Graham also cited Sanofi-Aventis' Arava as a drug he has recommended be withdrawn. Unlike the other five drugs, Arava has largely escaped the media spotlight, but there may yet be some tough questions asked about its safety.
Datamonitor

Free analysis: 'Barriers, best practices and measuring ROI for patient compliance programmes'

29 Nov 04

Unique intelligence from eyeforpharma: 'Barriers, best practices and measuring ROI for patient compliance programmes'
Izzy Wakeling

Tigecycline offers new hope in the battle against MRSA

26 Nov 04

Study data presented at a major recent conference has demonstrated that Wyeth's novel antibacterial tigecycline acts against drug-resistant pathogens in some serious bacterial infections, including MRSA. While Wyeth will have to work hard to establish tigecycline in this competitive area, its encouraging tolerability profile could give it a useful advantage over existing treatments.
Datamonitor

Influenza

19 Nov 04

Influenza is a global disease which imposes a huge medical and economic burden inevery country of the world. The UK is no exception with one caveat - the virus is probably monitored and tracked more in the UK than any other country around the globe. Over the years, GPs have played a leading role in estimating the quantitative impact of influenza. This started with the pioneering work of William Pickles in the Wensleydale villages and continued with Edgar Hope-Simpson in Cirencester.
CSF Medical

ADHD children not coming to attention of doctors

17 Nov 04

School can be a difficult place at the best of times, however for the 20 million plus children in the seven major pharmaceutical markets that suffer from attention deficit and hyperactivity disorder (ADHD), it can be especially troubling. This exacerbated by the fact that many patients aren't receiving the best available treatment, according to new research from Datamonitor.
Datamonitor

Hypertension and cardiovascular disease

09 Nov 04

Over the past 30 years, numerous clinical trials evaluating a variety of different classes of drugs have conclusively shown the benefit of blood pressure reduction in reducing the risk of strokes and cardiovascular mortality. Moreover, such trials have clearly demonstrated that blood pressure is unlikely to be controlled with a single drug and often two or more therapies are required to achieve blood pressure targets.
CSF Medical

Double trouble hits Altana respiratory pipeline

05 Nov 04

Altana has announced the delay of its US application for Daxas until late 2005 due to clinical trial enrolment taking longer than originally anticipated. The news will be of further concern to the company's investors, coming on the back of the recent announcement that another of its respiratory drugs, Alvesco, failed to win full FDA approval.
Datamonitor

Advertising